5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.
5 citations
,
November 2023 in “Journal of Ayurveda and Integrative Medicine” In this study, a case of Alopecia totalis was treated using cupping therapy along with ayurvedic treatments, suggesting that the combination may be effective due to the herbs' synergistic effects and cupping's immunostimulant activity.
January 2026 in “Annals of Dermatology” This source suggests that alitretinoin may be a safe and potentially effective treatment for patients with mild to moderate alopecia areata not responding to conventional therapies, though further research is needed to confirm its role, either alone or as an adjunct.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
January 2023 in “Figshare” This study reported that postmenopausal patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival over therapy-related side effects when considering cancer treatment decisions.
June 2026 in “Indian Dermatology Online Journal” In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.
1 citations
,
September 2007 in “Neuromuscular disorders” This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.
September 2023 in “Journal of The American Academy of Dermatology” In this study, researchers evaluated how subjects perceive the effectiveness of three FDA-cleared photobiomodulation devices for home use in treating androgenetic alopecia, though specific outcomes or comparative effectiveness are not reported in the abstract.
1 citations
,
January 2014 in “Jurnal Tata Rias” In this study, the hair tonic with a 3:3 avocado extract to honey ratio was most preferred by panelists and may be suitable for preventing hair loss.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, a case of alopecia areata was successfully treated using Ayurvedic medicine, highlighting its potential as an alternative to corticosteroids and immunosuppressants, which can have serious adverse effects with prolonged use.
August 2026 in “LUMEN ET VIRTUS” This study review reports that alopecia areata is often associated with autoimmune thyroid diseases like Hashimoto thyroiditis, suggesting targeted thyroid screening based on symptoms and risk factors may improve detection while minimizing unnecessary tests.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports a novel geometric medicine solution, N‑K GM SERIES, claiming to eliminate aflatoxin, offer a universal cancer cure, and provide numerous health benefits, including increased life expectancy, with deployment focused on the "Aflatoxin Belt" regions like Sudan.
September 2002 in “Oncology Times” This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.
66 citations
,
June 2020 in “Advanced Intelligent Systems” This review discusses the evolution of surgical robotics and examines the potential and current limitations of autonomous and intelligent systems in robotic-assisted surgeries.
January 2020 in “AYBU AVESIS” This study found no significant difference in 2D:4D ratios and autism questionnaire scores between acne vulgaris patients and healthy controls, despite investigating potential links in this novel context.
March 2026 in “Pediatric Dermatology” This study observed that GPT-4o, a generative AI model, showed high concordance with human providers in automating image-based SALT scores for assessing alopecia areata, suggesting its potential in assisting clinical evaluations without additional training.
January 2026 in “Vestnik dermatologii i venerologii” This review found that AI in dermatology shows high diagnostic accuracy comparable to experienced clinicians, but integration into clinical practice faces challenges requiring further research.
July 2026 in “Journal of the American Academy of Dermatology” April 2024 in “Institutional Repositories DataBase (IRDB)” This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.
This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.
January 2024 in “JEADV clinical practice” This article reviews how SALT scores are used in clinical trials for alopecia areata and provides patient images to help clinicians understand and apply these scores in practice; it reports no new clinical results.
6 citations
,
May 2023 in “Drugs” This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.
December 2022 in “Frontiers in plant science” This study identifies two new proteins, CCDC22 and CCDC93, essential for root and root hair growth in Arabidopsis, and demonstrates their genetic link to a VTI13-dependent vacuolar trafficking pathway.
February 2026 in “Skin Appendage Disorders” This study found that scalp microinfusion with dutasteride using microneedling and tattoo devices appears safe and shows promise as a treatment for male androgenetic alopecia, resulting in stabilization or improvement in 96.7% of patients, although further controlled studies are needed.
5 citations
,
June 2023 in “Engineering Technology & Applied Science Research” This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.
In this study, adding plum blossom needle tapping to finasteride treatment significantly improved the clinical efficacy and symptom scores for male patients with androgenic alopecia compared to finasteride alone.
42 citations
,
July 2013 in “Gene” This study found that intron 3 VNTR polymorphism in the IL-4 gene may be associated with an increased risk of alopecia areata in the Turkish population.
24 citations
,
April 2017 in “Aesthetic plastic surgery” In this study, micro-autologous fat transplantation (MAFT) for frontal augmentation using the MAFT-GUN showed high patient satisfaction and no complications among 178 patients, suggesting it may be a reliable method for forehead contouring.